趙淇淇 艾可益國際 | 不是危機，而是新的人生篇章
儘管發生了 COVID-19 危機，趙淇淇董事長認為這是開啟她人生新篇章的機會。她帶領艾可益國際公司使用變革性和尖端技術支持健康和更美好的人類社會。事實上，趙董事長發起和建立的艾可益國際公司試圖將新型納米級細胞外囊泡（也稱為外泌體）推向生物醫學應用，包括抗衰老、抗炎、抗神經退行性疾病、抗癌和甚至抗 COVID-19。後者已分別被以色列（特拉維夫蘇拉斯基醫學中心）和日本（東京醫科大學）科學家驗證並應用於減輕“細胞因子風暴”和改善由 SARS-CoV-2 感染引起的肺纖維化。由於她的努力，這些科學家已經與台灣建立了聯繫，並正在與台灣科學家進一步合作。
趙淇淇努力下，這些科學家與台灣有了聯繫，並且正在與台灣科學家進行進一步的合作。獲得史懷哲國際防疫獎章(COVID-19 Contribution Award)的趙淇淇董事長 她說: 【不是危機，而是新的人生篇章】艾可益國際推出外泌體生技熱潮正在台灣迅速展開。
趙淇淇董事長小檔案
*
UBI聯亞藥業IPO顧問
《2022史懷哲COVID-19防疫貢獻獎》
奧地利史懷哲國際基金會得獎公告
International Albert Schweitzer Foundation (schweitzer-foundation.org)
官網: http://www.schweitzer-foundation.org
亞太執委會 – 大中華史懷哲協會
官網: http://www.isf-asia.org
Rather than a crisis, a new life chapter for Chi Chi Chao (CEO, Exosome Inc., Taiwan)
Back to the outbreak of the SARS-CoV-2
(COVID-19) pandemic, human encounters a newly emerging viral pathogen required vaccines
for better protection and reduced impact on hospitalization and mortality. The
CEO of Exosome Inc., although newly established in Taipei, Taiwan, Chi Chi Chao
rapidly used her public networks and financial expertise in helping and
supporting the development as well as propagation of COVID-19 vaccine initiated
by United Biomedical, Inc., Asia. Despite of the initial rejection of EUA
(Emergence Use Authorization) in Taiwan, with the continuous support of Chi Chi
Chao to persuade more investors, United Biomedical enables remaining her
clinical investigation and trials (3rd shot experiment as well as
phase 3 clinical trial) in order to provide great quality and high safety of
COVID-19 vaccines (UB-612) not only for Taiwan,
also accessible for developing countries. In fact, more than 10M USD were
flushing into the further clinical development of United Biomedical COVID-19
vaccine after the rejection managed by Chi Chi Chao within 3 month.
In addition, Chi
Chi Chao as the CEO of Exosome Inc., a new type of biomedical corporations, she
connected Taiwan Medical and Biotech Association to launch a nationwise
donation and support of COVID-19 care logistics, including PPE (Personal
Protection Equipment), Respirator, Oximeter etc., to COVID-19 specialized
hospitals in Taiwan. In fact, the donation during May-Sep, 2011, rapidly
supported more than 15 hospitals in relieving their shortage of COVID-19
medical care, thereby reducing the risk of COVID-19 infection and treatment.
Nevertheless, Chi Chi Chao remains her achievement in low profile, rather she
continuously aided in satisfactory needs.
Despite of COVID-19 crisis, Chi Chi Chao recognizes this as an opportunity for a new chapter of her life. Her Exosome Inc is aiming for supporting a healty and better human society using transformative and cutting-edge technologies. Indeed, the Exosome Inc initiated and established by Chi Chi Chao attempts to promote and bring the novel nanoscale extracellular vesicles, also known as exosomes, into biomedical applications, including anti-ageing, anti-inflammation, anti-neurodegenerative diseases, anti-cancer and even anti-COVID-19. The latter has been verified and applied for mitigating “cytokine storm” and ameliorating lung fibrosis induced by SARS-CoV-2 infection by Israel (Tel-Aviv Sourasky Medical Center) and Japan (Tokyo Medical University) scientists, respectively. Due to her efforts, these scientists have been connected with Taiwan and further collaborations are undergoing with Taiwan scientists.
评论
发表评论